A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab

ABSTRACT: This study is to verify the advantage of FOLFOXIRI plus cetuximab over FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2195502 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR